関連レポート

医療診断用AI（人工知能）の世界市場：コンポーネント別、用途別2028年予測

サイト内検索

お探しの資料等をキーワード検索できます。英語検索も有効です。

出版元：Transparency Market Research 　 出版元について

発行年：2023年11月

定価 ：Single User License(1名様ライセンス)US$5,795(米国ドル)/Multi User License(5名様)$8,795 /Enterprise License $11,705

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

ご請求は円換算（お見積り日TTSレート）となります。

納品形態：PDF by Email

当調査レポートは英文173ページになります。

商品コード：TMR121

【レポート紹介】

関節リウマチ治療薬の世界市場規模は2022年で175億ドル、2031年に293億ドル、市場の平均年成長率は5.7%になる見込みです。

当レポートでは、関節リウマチ治療薬の市場予測-2031年、各種セグメント別市場分析(薬剤タイプ別、販売経路別、国地域別)、パイプライン分析、COVID-19の影響分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

■関節リウマチ治療薬の世界市場予測2023-2031年

・市場規模(US$)

■薬剤タイプ

非ステロイド性抗炎症薬（NSAID）
コルチコステロイド
疾患修飾性抗リウマチ薬（DMARD）
生体応答調節剤（BRM）
※(市場規模US$)

■販売経路

病院薬局
小売薬局
オンライン薬局
※(市場規模US$)

■主要国地域別市場-2031年

北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
南米
・ブラジル、メキシコ
・その他南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析

市場ダイナミクス（促進要因、障壁、機会）
パイプライン分析
COVID-19の影響分析
競合状況
市場シェア分析
SWOT分析

■関節リウマチ治療薬の主要企業プロフィール動向

AbbVie Inc.
Johnson & Johnson Innovative Medicine
Amgen Inc.
Pfizer Inc.
Novartis AG
Sanofi S.A.
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company

（全173頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

1. Executive Summary

    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology
3. Executive Summary: Global Rheumatoid Arthritis Drugs Market
4. Market Overview

    4.1. Market Segmentation
        4.1.1. Segment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, 2022-2031

5. Key Insights

    5.1. Pipeline Analysis
    5.2. Progression in Key Countries
    5.3. COVID-19 Pandemic Impact on Industry

6. Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Drug Type

    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Type, 2023–2031
        6.3.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        6.3.2. Corticosteroids
        6.3.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
        6.3.4. Biologic Response Modifiers (Biologics)
    6.4. Market Attractiveness, by Drug Type

7. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Distribution Channel

    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Distribution Channel, 2023–2031
        7.3.1. Hospital Pharmacy
        7.3.2. Retail Pharmacy
        7.3.3. Online Pharmacy
    7.4. Market Attractiveness, by Distribution Channel

8. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Region

    8.1. Key Findings
    8.2. Market Value Forecast, by Region, 2023–2031
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness, by Region

9. North America Rheumatoid Arthritis Drugs Market Analysis and Forecast

    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, by Drug Type, 2022–2031
        9.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        9.2.2. Corticosteroids
        9.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
        9.2.4. Biologic Response Modifiers (Biologics)
    9.3. Market Value Forecast, by Distribution Channel, 2022–2031
        9.3.1. Hospital Pharmacy
        9.3.2. Retail Pharmacy
        9.3.3. Online Pharmacy
    9.4. Market Value Forecast, by Country, 2022–2031
        9.4.1. U.S.
        9.4.2. Canada
    9.5. Market Attractiveness Analysis
        9.5.1. By Drug Type
        9.5.2. By Distribution Channel
        9.5.3. By Country

10. Europe Rheumatoid Arthritis Drugs Market Analysis and Forecast

    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Type, 2022–2031
        10.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        10.2.2. Corticosteroids
        10.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
        10.2.4. Biologic Response Modifiers (Biologics)
    10.3. Market Value Forecast, by Distribution Channel, 2022–2031
        10.3.1. Hospital Pharmacy
        10.3.2. Retail Pharmacy
        10.3.3. Online Pharmacy
    10.4. Market Value Forecast, by Country/Sub-region, 2022–2031
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Italy
        10.4.5. Spain
        10.4.6. Rest of Europe
    10.5. Market Attractiveness Analysis
        10.5.1. By Drug Type
        10.5.2. By Distribution Channel
        10.5.3. By Country/Sub-region

11. Asia Pacific Rheumatoid Arthritis Drugs Market Analysis and Forecast

    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Type, 2022–2031
        11.2.1. Polycarbonate (PC) Compound
        11.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        11.2.3. Corticosteroids
        11.2.4. Disease Modifying Anti-rheumatic Drugs (DMARDs)
        11.2.5. Biologic Response Modifiers (Biologics)
    11.3. Market Value Forecast, by Distribution Channel, 2022–2031
        11.3.1. Hospital Pharmacy
        11.3.2. Retail Pharmacy
        11.3.3. Online Pharmacy
    11.4. Market Value Forecast, by Country/Sub-region, 2022–2031
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. Australia & New Zealand
        11.4.5. Rest of Asia Pacific
    11.5. Market Attractiveness Analysis
        11.5.1. By Drug Type
        11.5.2. By Distribution Channel
        11.5.3. By Country/Sub-region

12. Latin America Rheumatoid Arthritis Drugs Market Analysis and Forecast

    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Type, 2022–2031
        12.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        12.2.2. Corticosteroids
        12.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
        12.2.4. Biologic Response Modifiers (Biologics)
    12.3. Market Value Forecast, by Distribution Channel, 2022–2031
        12.3.1. Hospital Pharmacy
        12.3.2. Retail Pharmacy
        12.3.3. Online Pharmacy
    12.4. Market Value Forecast, by Country/Sub-region, 2022–2031
        12.4.1. Brazil
        12.4.2. Mexico
        12.4.3. Rest of Latin America
    12.5. Market Attractiveness Analysis
        12.5.1. By Drug Type
        12.5.2. By Distribution Channel
        12.5.3. By Country/Sub-region

13. Middle East & Africa Rheumatoid Arthritis Drugs Market Analysis and Forecast

    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Type, 2022–2031
        13.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        13.2.2. Corticosteroids
        13.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
        13.2.4. Biologic Response Modifiers (Biologics)
    13.3. Market Value Forecast, by Distribution Channel, 2022–2031
        13.3.1. Hospital Pharmacy
        13.3.2. Retail Pharmacy
        13.3.3. Online Pharmacy
    13.4. Market Value Forecast, by Country/Sub-region, 2022–2031
        13.4.1. GCC Countries
        13.4.2. South Africa
        13.4.3. Rest of Middle East & Africa
    13.5. Market Attractiveness Analysis
        13.5.1. By Drug Type
        13.5.2. By Distribution Channel
        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    14.2. Market Share Analysis, by Company (2022)
    14.3. Company Profiles
        14.3.1. AbbVie Inc.
            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.1.2. Product Portfolio
            14.3.1.3. Financial Overview
            14.3.1.4. SWOT Analysis
            14.3.1.5. Strategic Overview
        14.3.2. Johnson & Johnson Innovative Medicine
            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.2.2. Product Portfolio
            14.3.2.3. Financial Overview
            14.3.2.4. SWOT Analysis
            14.3.2.5. Strategic Overview
        14.3.3. Amgen Inc.
            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.3.2. Product Portfolio
            14.3.3.3. Financial Overview
            14.3.3.4. SWOT Analysis
            14.3.3.5. Strategic Overview
        14.3.4. Pfizer Inc.
            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.4.2. Product Portfolio
            14.3.4.3. Financial Overview
            14.3.4.4. SWOT Analysis
            14.3.4.5. Strategic Overview
        14.3.5. Novartis AG
            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.5.2. Product Portfolio
            14.3.5.3. Financial Overview
            14.3.5.4. SWOT Analysis
            14.3.5.5. Strategic Overview
        14.3.6. Sanofi S.A.
            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.6.2. Product Portfolio
            14.3.6.3. Financial Overview
            14.3.6.4. SWOT Analysis
            14.3.6.5. Strategic Overview
        14.3.7. F. Hoffmann-La Roche Ltd.
            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.7.2. Product Portfolio
            14.3.7.3. Financial Overview
            14.3.7.4. SWOT Analysis
            14.3.7.5. Strategic Overview
        14.3.8. Merck & Co., Inc.
            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.8.2. Product Portfolio
            14.3.8.3. Financial Overview
            14.3.8.4. SWOT Analysis
            14.3.8.5. Strategic Overview
        14.3.9. Bristol-Myers Squibb Company
            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.9.2. Product Portfolio
            14.3.9.3. Financial Overview
            14.3.9.4. SWOT Analysis
            14.3.9.5. Strategic Overview
        14.3.10. Eli Lilly and Company
            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.10.2. Product Portfolio
            14.3.10.3. Financial Overview
            14.3.10.4. SWOT Analysis
            14.3.10.5. Strategic Overview

List of Tables

Table 1: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031

Table 2: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031

Table 3: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Region, 2023–2031

Table 4: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country, 2023–2031

Table 5: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031

Table 6: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031

Table 7: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

Table 8: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031

Table 9: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031

Table 10: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

Table 11: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031

Table 12: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031

Table 13: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

Table 14: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031

Table 15: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031

Table 16: Middle East & Africa Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

Table 17: Middle East & Africa Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031

Table 18: Middle East & Africa Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031

List of Figures

Figure 1: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023–2031

Figure 2: Global Rheumatoid Arthritis Drugs Market Value Share, by Drug Type, 2022

Figure 3: Global Rheumatoid Arthritis Drugs Market Value Share, by Distribution Channel, 2022

Figure 4: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 5: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 6: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 7: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 8: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Region, 2022 and 2031

Figure 9: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Region, 2023–2031

Figure 10: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023–2031

Figure 11: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country, 2022 and 2031

Figure 12: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country, 2023–2031

Figure 13: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 14: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 15: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 16: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 17: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023–2031

Figure 18: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 19: Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 20: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 21: Europe America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 22: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 23: Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 24: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023–2031

Figure 25: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 26: Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 27: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 28: Asia Pacific America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 29: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 30: Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 31: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023–2031

Figure 32: Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 33: Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 34: Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 35: Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 36: Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 37: Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Middle East & Africa America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2023–2031

Figure 39: Middle East & Africa America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 40: Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 41: Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 42: Global Rheumatoid Arthritis Drugs Market Share Analysis, by Company (2022)